Oxaliplatin+S-1

Phase 2Small molecule

SSixth Affiliated Hospital, Sun Yat-sen University

Oxaliplatin+S-1 is one of 53 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Erbitux

IImclone

Phase 3

11 2

Sugammadex Sodium

KKorea University Anam Hospital

Phase 3

1 3

Gemzar

Johnson & Johnson

Preclinical

—4

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 5

Oxaliplatin+S-1

SSixth Affiliated Hospital, Sun Yat-sen University

Phase 2

2 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Induction Phase1

Genmab

Preclinical

1 9

Glutamine

Sanofi

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Adenocarcinoma

NCT04989985

Clinical

Trials by Indication[1]

Gastric Cancer2 trials

SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer

Unknown status·LLin Chen·Phase 3·NCT01583361·772 enrolled

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Unknown status·—·Phase 1/2·NCT02317471·45 enrolled

Adenocarcinoma1 trial

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT04989985·302 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Oxaliplatin+S-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaliplatin+S-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaliplatin+S-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sixth Affiliated Hospital, Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSixth Affiliated Hospital, Sun Yat-sen University

Oxaliplatin+S-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Gastric Cancer2 trials

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News